Dr. Reddy's Files First Orencia Biosimilar Application with FDA, Targeting $2.77 Billion Market
核心洞察
Dr. Reddy's announced the filing of the first publicly disclosed aBLA for an Orencia (abatacept) biosimilar in December 2025, targeting Bristol-Myers Squibb (搜索)'s $2.77 billion U.S. market.
The company plans to launch its intravenous formulation by the end of 2026, followed by a subcutaneous version in early 2028, with no current patent disputes blocking market entry.
Dr. Reddy's appears positioned as the first company to launch an abatacept biosimilar globally, as no other companies have completed Phase III trials for this indication.
Dr. Reddy's Laboratories has filed an abbreviated Biologics License Application (aBLA) with the FDA for DRL_AB (搜索), a proposed biosimilar of Bristol-Myers Squibb (搜索)'s Orencia (abatacept), marking the first publicly disclosed regulatory submission for an abatacept biosimilar. The Indian pharmaceutical company announced the December 2025 filing during its January 21, 2026 earnings call, targeting a market worth $2.77 billion in U.S. sales for the reference product.
Market Entry Timeline and Formulations
Dr. Reddy's has outlined an ambitious launch strategy for its abatacept biosimilar program. The company expects to launch its intravenous (IV) formulation of DRL_AB (搜索) by the end of 2026, pending regulatory approval. Additionally, the company is developing a subcutaneous formulation that it hopes to launch in early 2028, providing patients with multiple administration options.
According to statements made during the earnings call, Dr. Reddy's appears to have a significant competitive advantage in the abatacept biosimilar space. The company indicated that no other companies have completed Phase III trials for abatacept biosimilars, potentially positioning Dr. Reddy's as the first to launch a biosimilar in both the U.S. and European markets.
Clear Regulatory Path
The regulatory landscape for Orencia biosimilars appears favorable for Dr. Reddy's market entry. Currently, there are no pending patent disputes related to Orencia, and no patents are listed for the drug in the FDA's Purple Book. This clear intellectual property environment could facilitate a smoother path to market launch without the typical patent litigation challenges that often accompany biosimilar launches.
Company's Biosimilar Expertise
Dr. Reddy's brings substantial experience to the abatacept biosimilar development. Over the past 25 years, the company has developed a fully integrated biologics organization with robust capabilities in development, manufacturing, and commercialization of biosimilar products in oncology and immunology. The company currently maintains a portfolio of six commercial biosimilar products marketed in India, with some products available in more than 30 other countries.
Recent biosimilar launches demonstrate the company's growing global presence. In 2024, Dr. Reddy's launched its first biosimilar in the United Kingdom with Versavo (biosimilar bevacizumab), following launches of pegfilgrastim in the U.S. and Europe through partnerships. The company also launched its rituximab biosimilar in Europe in 2025, establishing a track record of successful biosimilar commercialization in major markets.